The following table lists the monoclonal antibodies specific for equine cytokines, chemokines, immunoglobulins, and CD markers developed by Dr. Bettina Wagner's laboratory at Cornell University.
To obtain monoclonal antibodies, please contact Dr. Bettina Wagner.
Last updated: August 11, 2023
| Group of Molecules | Specificity (anti-equine) | Clone | Mouse Isotype | Methods Tested | Reference |
|---|---|---|---|---|---|
| Cytokines | IL-2 | 158-1 | IgG1 | FACS, ELISA, western blot, bead-based multiplex assay | Freer et al. 2017. Abstract |
| IL-4 | 25 | IgG1 | FACS, ELISA, bead-based multiplex assay | Wagner et al. 2012. Abstract | |
| 13G7 | IgG1 | FACS, ELISA, bead-based multiplex assay | Wagner et al. 2006. Abstract | ||
| IL-10 | 165-1 | IgG1 | FACS, ELISA | Wagner et al. 2007. Abstract | |
| 492-1 | IgG2b | FACS, ELISA, bead-based multiplex assay | |||
| 492-2 | IgG1 | FACS, ELISA, bead-based multiplex assay | |||
| IL-17A | 76 | IgG1 | FACS, ELISA | Perkins et al. 2014. Abstract | |
| 79-3 | IgG1 | ELISA, bead-based multiplex assay | Wagner et al. 2015. Abstract | ||
| 80-1 | IgG1 | ELISA, bead-based multiplex assay | |||
| IFN-α | 29B | IgG1 | Low neutralizing activity, ELISA | Wagner et al. 2008. Abstract | |
| 240-2 | IgG1 | High neutralizing activity, ELISA, bead-based multiplex assay | |||
| 150 | IgG2b | No neutralizing activity, bead-based multiplex assay | |||
| IFN-γ | 3 | IgG1 | ELISA, bead-based multiplex assay | Wagner et al. 2015. Abstract | |
| 36 | IgG1 | ELISA, bead-based multiplex assay | |||
| 38-1 | IgG1 | FACS | |||
| TNF-α | 48 | IgG1 | FACS, ELISA, bead-based multiplex assay | Schnabel et al. 2021. Abstract | |
| 292 | IgG1 | ||||
| Chemokines | CCL2 | 49 | IgG1 | ELISA, bead-based multiplex assay | Schnabel et al. 2018. Abstract |
| 53 | IgG1 | FACS, ELISA | |||
| 104-2 | IgG1 | ELISA, bead-based multiplex assay | |||
| CCL3 | 77 | IgG1 | ELISA, bead-based multiplex assay | ||
| 289 | IgG1 | ELISA, bead-based multiplex assay | |||
| 290 | IgG1 | FACS | |||
| CCL5 | 46 | IgG1 | ELISA, bead-based multiplex assay | ||
| 91 | IgG1 | ELISA, bead-based multiplex assay | |||
| 96 | IgG1 | FACS | |||
| CCL11 | 24 | IgG1 | FACS, ELISA, bead-based multiplex assay | ||
| 25 | IgG1 | ||||
| IL-8 | 321-2 | IgG1 | FACS | Larson et al. 2021. Abstract | |
| CXCL10 | 44-2 | IgG1 | FACS | Schnabel et al. 2019. Abstract | |
| Immunoglobulins | IgM | 1-22 | IgG1 | Western blot, ELISA, West Nile virus IgM capture | Wagner et al. 2007. Abstract |
| 2B-63 | IgG1 | ||||
| IgG1/3 | 159 | IgG1 | ELISA, bead-based multiplex assay | Keggan et al. 2013. Abstract | |
| IgG3/5 | 586 | IgG1 | ELISA, bead-based multiplex assay | ||
| IgG5 | 416-2 | IgG2a | ELISA, bead-based multiplex assay | ||
| 522 | IgG1 | ELISA | |||
| IgG6 | 125-1 | IgG1 | ELISA, bead-based multiplex assay | ||
| 267 | IgG1 | ELISA, bead-based multiplex assay | |||
| IgE | 134 | IgG1 | FACS, ELISA, western blot | Wagner et al. 2003. Abstract | |
| 176 | IgG1 | ||||
| IgA | 84-1 | IgG1 | FACS, Western blot, bead-based multiplex assay | Schnabel et al. 2017. Abstract | |
| 161-1 | IgG1 | ||||
| CD Marker | CD14 | 105 | IgG1 | FACS, cell sorting, ELISA, bead-based multiplex assay | Kabithe et al. 2010. Abstract |
| 59 | IgG2b | Western blot, ELISA, bead-based multiplex assay | Wagner et al. 2013. Abstract | ||
| CD23 | 51-3 | IgG1 | FACS | Wagner et al. 2012. Abstract | |
| 54-3 | IgG1 | Western blot | |||
| 63-2 | IgG1 | ||||
| CD25 | 15-1 | IgG1 | FACS | Not yet published | |
| 28-1 | IgG1 | ||||
| 54-2 | IgA |
mAbs under development
mAbs for the following equine immune targets are currently under development and can be obtained for confirmatory testing before they are added to the chart above. Note that the specificity of the mAbs below is not yet confirmed.
- IL-1β (specificity for native protein confirmed by FACS on stimulated PBMC, currently tested for ELISA and bead-based multiplex assays)
- IL-6 (further characterized for flow cytometry)
- IgD (flow cytometric and ELISA characterization)
- SLPI (tested for secretion assay, flow cytometric characterization ongoing)
- Granulysin (limiting dilution cloning and FACS characterization)
Targets not resulting in a mAb
The following targets were approached and dropped during our reagent development projects for the horse because they did not result in a specific mAb. A brief reason for development failure is given for each target. For more information, please contact Dr. Bettina Wagner.
- TCR constant region (low immunogenicity, no native TCR recognition)
- TLR (difficult to express in soluble form)
- IL-13 (low immunogenicity)
- IFN-β (low immunogenicity)
- CXCL9 (low immunogenicity)
- NCR2 (low immunogenicity)
- CD19 (low immunogenicity)
Antibody development was funded by USDA/NIFA grants as part of the US-VIRN project, the Equine Immune Reagent Development grant, the Morris Animal Foundation, and the Harry M. Zweig Memorial Fund for Equine Research at Cornell University.